Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protease Overexpression Facilitates Breast Cancer Spread

By LabMedica International staff writers
Posted on 07 Feb 2012
In breast cancer the loss of the tumor suppressor gene Lkb1 (liver kinase B1) causes overexpression of hepsin, a protease that degrades and disrupts the basement membrane (BM) structure that holds the tumor together.

Cancer researchers have sought to understand the mechanism that causes a highly structured tumor to break out of its site of initial growth and to spread to other tissues. More...
In the current study investigators at the University of California, San Francisco (UCSF; USA) and the University of Helsinki (Finland) looked at the relationship between Lkb1, which is missing in about 25% of breast tumors, and hepsin, which is highly expressed in those tumors.

They reported in the January 20, 2012, online edition of the journal Proceedings of the [US] National Academy of Sciences that studies conducted on breast cancel mouse models and on breast cancer cell cultures had revealed that conditional deletion of Lkb1 in the mammary gland caused overexpression of the cell membrane protein hepsin. Increased hepsin activity resulted in compromised epithelial integrity. This was manifested by mislocalization of cell polarity markers, lateralization of tight junctions, deterioration of desmosomes and basement membrane (BM), and hyperbranching of the mammary ductal tree. Deactivation of hepsin allowed the basement membrane to recover.

These results showed that hepsin was a key factor mediating Lkb1 loss-induced structural alterations in mammary epithelium and BM fragmentation. Although loss of Lkb1 alone did not promote mammary tumorigenesis, the combination of Lkb1 deficiency and activation of the oncogene c-Myc led to dramatic acceleration in tumor formation.

“If we could delay or prevent a tumor from switching from one that grows in place to one that invades, then that would be a major milestone in cancer treatment,” said contributing author Dr. Zena Werb, professor of anatomy at UCSF. “We have observed that loss of Lkb1 combined with activation of a weak inducer of breast cancer – an oncogene such as Myc — can produce aggressive cancers. In humans, breast cancers that have diminished amounts of Lkb1 show strong hepsin expression. Since hepsin sits on the cell membrane, it should be accessible to drugs. We believe that hepsin forms a novel target for treatment of a subset of breast cancer patients.”

Related Links:

University of California, San Francisco
University of Helsinki



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.